Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma - Wikidata - awgldk - TriplyDB

Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma

Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma

http://www.wikidata.org/entity/Q34144940

about

CD47: A Cell Surface Glycoprotein Which Regulates Multiple Functions of Hematopoietic Cells in Health and Disease Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47 Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies.Therapeutic opportunities for targeting the ubiquitous cell surface receptor CD47 Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy Thrombospondin-1 signaling through CD47 inhibits self-renewal by regulating c-Myc and other stem cell transcription factors Interplay between Cellular and Molecular Inflammatory Mediators in Lung Cancer Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: impact on clinical studies and considerations for combined therapies Apoptotic cell clearance: basic biology and therapeutic potential.Mechanisms driving macrophage diversity and specialization in distinct tumor microenvironments and parallelisms with other tissues Understanding dendritic cells and their role in cutaneous carcinoma and cancer immunotherapy Macrophages: gatekeepers of tissue integrity Targeting the innate immune system as immunotherapy for acute myeloid leukemia Lymphoma: immune evasion strategies CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest The CD47-binding peptide of thrombospondin-1 induces defenestration of liver sinusoidal endothelial cells CD47 agonist peptides induce programmed cell death in refractory chronic lymphocytic leukemia B cells via PLCγ1 activation: evidence from mice and humans Integrative network modeling approaches to personalized cancer medicine Registered report: the CD47-signal regulated protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors Cancer immunotherapy via dendritic cells The Dynamics of Apoptotic Cell Clearance Penetration of antibody-opsonized cells by the membrane attack complex of complement promotes Ca(2+) influx and induces streamers.The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging Antibody Therapies in Cancer.PEDF increases the tumoricidal activity of macrophages towards prostate cancer cells in vitro.Anti-CD47 Antibody As a Targeted Therapeutic Agent for Human Lung Cancer and Cancer Stem Cells.Immune checkpoint blockade for hematologic malignancies: a review Current status and perspectives of patient-derived xenograft models in cancer research.Engineering humanized mice for improved hematopoietic reconstitution.Molecular Checkpoint Decisions Made by Subverted Vascular Niche Transform Indolent Tumor Cells into Chemoresistant Cancer Stem Cells Chemotherapy and tumor microenvironment of pancreatic cancer.CD47 promotes ovarian cancer progression by inhibiting macrophage phagocytosis IAP antagonists induce anti-tumor immunity in multiple myeloma.ISL-1 is overexpressed in non-Hodgkin lymphoma and promotes lymphoma cell proliferation by forming a p-STAT3/p-c-Jun/ISL-1 complex Potentiating antilymphoma efficacy of chemotherapy using a liposome for integration of CD20 targeting, ultra-violet irradiation polymerizing, and controlled drug delivery.Co-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer patients

P2860

Q21284814-C1145720-78C5-41FF-BE87-591E1EBD85AB Q24561405-4428361B-5D03-4DDB-99D8-724F52BF9691 Q24602822-CE0B7F53-3B16-484C-BC52-C51CAB4E3D1E Q24605052-F09BB7B5-619E-4FE1-86D2-9BB851746603 Q24605057-62DF4CA2-8896-44E5-B553-2AE0B195D9C8 Q24627155-A0257748-545E-4518-8846-B5C69B7B2374 Q24631455-654A76E8-54B3-4EF3-A4B7-ABCB6C0195A7 Q24631515-A1167AAF-59A3-436F-8363-0C0E7FD50146 Q24631961-E375BD9F-2F12-4F76-929B-1B068B6EA939 Q24633525-1ED92378-3804-4E84-B483-9BB8AEBA0305 Q26768652-C3318DCD-5BD6-4938-B0A8-3528D7992E98 Q26781215-1EAF9098-4773-4A8C-91EA-EB964A65C13E Q26825935-545CBFAF-E231-497A-97AE-118575658078 Q27003907-4395147C-BBDA-4A3B-B879-F7E2B45005E8 Q27004702-98B5BC6A-E0D0-4D71-A5BA-120AE2622C69 Q27007092-BF4D02F1-867F-4117-AF3A-2ABD31EC6D2F Q27015876-2BA3C21A-781B-435B-8EFC-9C82D3866021 Q28080705-D3DE1226-46E8-4B33-9F64-45EB83E6403D Q28270624-2296FB50-33C7-4295-B6A7-036BE6DE9174 Q28293417-852A1E14-751D-4E1B-B483-B48D8F15A915 Q28543785-13B12836-9D75-4AE0-9716-C3BEA663CD02 Q28602016-97A66DFE-D74F-4E76-A9DD-158AFC044C6F Q28650496-F8667B5B-69C1-4BDA-8E47-0FE211DDC82A Q29615444-2F798338-CE67-479B-BFCA-CD31F549EECB Q30276273-6D9F401B-E249-4847-9170-E0BA2563936F Q30453680-1CFDD967-E95F-45CD-A71D-E1202057E3FF Q30559277-C27DAA98-04C2-4228-A9C3-33466B53DE7B Q31104000-8EEC7E57-AC7C-434A-AE42-A9EFE4E25396 Q33558122-09607CEF-C7A1-4468-8D4A-16E98197C087 Q33586204-95D1BCAC-ED23-43C1-A9F0-3D766B541430 Q33645590-CB0F476A-5B3D-4275-A943-205729BA80EA Q33667686-CEDFC2AC-579C-4835-A4A3-1A163AED2AC6 Q33844310-A2E88F44-6243-4EC7-816B-4AFA18279E7B Q33872400-608FF96D-1882-49AF-AC71-866E3AC8D699 Q33876637-138350F9-086A-467B-8BEC-56071EE4B7BD Q33889065-3F649374-D6D4-4582-A781-6C7DF959AAA3 Q33914862-0BFDC4F3-0704-4B9D-AAA2-1758C110A50A Q34016520-9C7B9E34-B19C-4902-B4E3-A9132ED9488C Q34116979-257E7EB4-0B49-4E22-9A43-16D9D8EAFC49 Q34483478-A98690E8-96DD-49D3-9CE0-8B25321844D7

P2860

Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma

http://www.wikidata.org/entity/Q34144940

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Anti-CD47 antibody synergizes ...... eradicate non-Hodgkin lymphoma

@ast

Anti-CD47 antibody synergizes ...... eradicate non-Hodgkin lymphoma

@en

Anti-CD47 antibody synergizes ...... eradicate non-Hodgkin lymphoma

@nl

type

label

Anti-CD47 antibody synergizes ...... eradicate non-Hodgkin lymphoma

@ast

Anti-CD47 antibody synergizes ...... eradicate non-Hodgkin lymphoma

@en

Anti-CD47 antibody synergizes ...... eradicate non-Hodgkin lymphoma

@nl

prefLabel

Anti-CD47 antibody synergizes ...... eradicate non-Hodgkin lymphoma

@ast

Anti-CD47 antibody synergizes ...... eradicate non-Hodgkin lymphoma

@en

Anti-CD47 antibody synergizes ...... eradicate non-Hodgkin lymphoma

@nl

P1433

Q34144940-BA38F9AE-01BC-43B4-ACE9-BFDB6076F0C1

P1476

Q34144940-A4CEF4D4-3841-4503-8612-430FF120D237

P2093

Q34144940-1AD73629-2B03-4405-9DA7-8F4C78B4F3D1

Q34144940-1F182077-1A61-4A6E-9650-E7E7E543016D

Q34144940-2A52AF6B-2481-4DC6-BC2E-78090EC2D85C

Q34144940-2B0D0C18-6F9E-459D-B698-3607E67495EC

Q34144940-4F8B649D-ECC3-47FD-8BBF-BB9598B04FE8

Q34144940-5193CDEE-446F-4C53-9F00-1429FF19BD13

Q34144940-5DDA7219-9882-4CF8-B37F-6C46C211D517

Q34144940-67A4E3C9-7C55-4FB0-806F-62E4950525F4

Q34144940-829A3D9F-EAF3-4642-9864-00D2AEEFD468

Q34144940-83A17464-71C5-476F-A36C-A05738DC1F22

P2860

Q34144940-01CC0E40-2E4B-4D6A-967A-3BC642751592

Q34144940-0E3427FE-F6AE-43B0-9C12-CBBEC5809BBA

Q34144940-1382616A-E48C-4468-A13D-46802F58742D

Q34144940-19B89ECD-964F-4E71-B9CD-2E822EA4763F

Q34144940-2D53AA33-496E-46BE-9D64-C8AEDA597857

Q34144940-375A42C8-5571-4938-8C05-43378A64233C

Q34144940-3954368E-E25B-4BD4-A230-B969D37ACBF2

Q34144940-3AFDBA63-F2C8-41C4-AF08-707773CF9CDB

Q34144940-3F4F3DA9-AEAB-420B-8F69-6CE56154B8C1

Q34144940-43D582B2-3E5D-4F63-B909-3DC96CFBD03C

P304

Q34144940-4FE2FB2D-8AD7-4537-BF3E-729B503B9679

P31

Q34144940-71CC4623-4114-4E3B-8131-6C9C0904BB82

P356

Q34144940-8AF05562-6E11-4FBD-BA50-AA37AF7A536A

P407

Q34144940-9D7C7791-E8C0-4FC6-803C-259DF9A5A520

P433

Q34144940-EFEED198-FB2B-49B7-A6AC-AFB73420843A

P478

Q34144940-05CFB4F2-EA1D-4297-909E-09DE074D5D5E

P50

Q34144940-4331D7D6-50A3-426D-AC6C-934F8B4C1172

Q34144940-697C5E10-62ED-4FE4-B8CD-5059C8E640F6

P577

Q34144940-07851D75-5BF8-4A56-A8EA-6CA823D6557A

P5875

Q34144940-2C25ED8D-0F76-4F1C-B0EB-DC722952B428

P698

Q34144940-BD058AD8-A49F-4A10-9766-8EA69EBC3FAC

P921

Q34144940-9A6A27DA-2998-4C4C-B029-75A6F67385B6

Q34144940-AA26E3DC-2D0B-4862-9780-35403573D53D

P932

Q34144940-E83A3B97-D249-47C9-8A1E-197187A8B268

P356

J.CELL.2010.07.044

P1433

P1476

Anti-CD47 antibody synergizes ...... eradicate non-Hodgkin lymphoma

@en

P2093

Adriel C Cha

http://www.w3.org/2001/XMLSchema#string

Ash A Alizadeh

http://www.w3.org/2001/XMLSchema#string

Bindu Varghese

http://www.w3.org/2001/XMLSchema#string

Brent T Tan

http://www.w3.org/2001/XMLSchema#string

Chad Tang

http://www.w3.org/2001/XMLSchema#string

Charles K Chan

http://www.w3.org/2001/XMLSchema#string

Christopher Y Park

http://www.w3.org/2001/XMLSchema#string

Feifei Zhao

http://www.w3.org/2001/XMLSchema#string

Holbrook E Kohrt

http://www.w3.org/2001/XMLSchema#string

Irving L Weissman

http://www.w3.org/2001/XMLSchema#string

P2860

Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells

CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

CD47 ligation induces caspase-independent cell death in chronic lymphocytic leukemia

Integrin-associated protein (CD47) and its ligands

Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma

Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia.

P304

699-713

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CELL.2010.07.044

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

142

http://www.w3.org/2001/XMLSchema#string

P50

June H. Myklebust

Randy D Gascoyne

P577

2010-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46123750

http://www.w3.org/2001/XMLSchema#string

P698

20813259

http://www.w3.org/2001/XMLSchema#string

P921

P932

2943345

http://www.w3.org/2001/XMLSchema#string